Open-label Study with Nalmefene as Needed Use in Alcohol-Dependent Patients with Evidence of Elevated Liver Stiffness and/or Hepatic Steatosis.
Aims This open-label study in patients with alcohol dependence and evidence of elevated liver stiffness and/or hepatic steatosis was designed to explore the efficacy of nalmefene (18 mg) in reducing alcohol consumption and its subsequent effects on a variety of clinically relevant liver parameters....
| Publicado en: | Alcohol & Alcoholism Vol. 55; no. 1; pp. 63 - 71 |
|---|---|
| Autores principales: | , , , , , |
| Formato: | clinical trial research tables/charts Journal Article |
| Publicado: |
Oxford University Press / USA
Jan2020
|
| Acceso en línea: | Ver este registro en EBSCOhost |